Investment Focus - Oaktree Acquisition Corp. III is focused on identifying business combination opportunities primarily in the healthcare or healthcare-related industries, particularly in North America, the UK, and Western Europe[26]. - The management team is focused on identifying, acquiring, and building companies in the healthcare and healthcare-related industries, including biopharmaceuticals, medical devices, diagnostics, and specialized healthcare services[53]. - The healthcare sector is expected to continue growing due to technological advancements and an aging population, with significant capital required for R&D and commercialization of new products[36]. Financial Overview - Oaktree has approximately $202 billion in assets under management as of December 31, 2024, with $18.3 billion allocated to private equity strategies[28]. - The company has $193,579,022 available for a business combination as of December 31, 2024, including $6,719,660 of deferred underwriting fees[107]. - The total funds in the trust at the closing of the initial public offering amount to $191,990,290, which will be used for the initial business combination[211]. Investment Strategy - Oaktree's Life Sciences team evaluated over 800 investment opportunities, with only 51 investments being consummated, indicating a selective investment approach[33]. - The acquisition strategy aims to leverage Oaktree's proprietary deal sourcing network, which combines industry research and relationships to identify unique business combination opportunities[54]. - Target companies are expected to have an enterprise value between $500 million and $1.5 billion, with a focus on those that are resilient to economic cycles and possess attractive cash flow profiles[60]. Management Team - The management team has prior experience with SPACs, successfully completing business combinations with Hims & Hers Health, Inc. and Alvotech Holdings S.A.[37][38]. - The management team includes experienced professionals with backgrounds in healthcare and finance, enhancing the company's ability to identify and evaluate potential targets[34]. - The management team has extensive experience in operating companies in both public and private markets, defining corporate strategy, and growing companies through strategic transactions[55]. Due Diligence and Acquisition Process - The management team plans to conduct thorough due diligence, including meetings with management, document reviews, and inspections of facilities, to evaluate prospective target businesses[61]. - The acquisition process will include obtaining an independent opinion on the fairness of any business combination with affiliated companies to mitigate potential conflicts of interest[62]. - A thorough due diligence review will be conducted for prospective target businesses, including meetings with management and document reviews[119]. Shareholder Considerations - Public shareholders can redeem Class A ordinary shares at a price of $10.00 per share upon completion of the initial business combination[137]. - A total of 6,907,646 public shares, or 35.98% of the 19,199,029 public shares sold in the initial public offering, must be voted in favor for the business combination to be approved[142]. - Shareholders holding more than 15% of public shares are restricted from seeking redemption rights without prior consent, aimed at preventing coercive redemption practices[147]. Risks and Conflicts of Interest - The company’s management team may face conflicts of interest due to their ownership of ordinary shares and private placement units following the initial public offering[63]. - Conflicts of interest may arise due to the economic interests of the sponsor and board members in the founder shares[87]. - The company may not be able to generate sufficient value from its initial business combination to overcome the dilutive impact of various factors, potentially resulting in a net loss for investors[205]. Timeline and Extensions - The company must complete its initial business combination within 24 months of its initial public offering, or it will cease operations and liquidate, redeeming public shares[195]. - The company may seek shareholder approval to extend the time to consummate its initial business combination beyond the initial 24-month period, with a maximum extension of up to 36 months[95]. - There is no limit on the number of extensions the company may seek, but it does not expect to extend beyond 36 months from the IPO closing[225]. Redemption and Liquidation - If the initial business combination is not completed, public shareholders who elected to redeem their shares will not be entitled to any pro rata share of the trust account[153]. - The per-share redemption amount upon dissolution is expected to be $10.00, but this could be reduced if claims from creditors deplete the trust account[159]. - If the company fails to complete a business combination within the required timeframe, it will cease operations and redeem public shares at a price equal to the amount in the trust account, potentially less than $10.00 per share[222].
Oaktree Acquisition Corp. III Life Sciences(OACCU) - 2024 Q4 - Annual Report